Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Brazil to seek regulatory approval for AstraZeneca vaccine on Jan. 15

Mon, 28th Dec 2020 21:18

(Adds comments by health official and Bolsonaro, background,
details)

By Pedro Fonseca

RIO DE JANEIRO, Dec 28 (Reuters) - Brazil's Fiocruz
biomedical institute will seek approval for the Oxford
University/AstraZeneca vaccine against COVID-19 with
federal health regulator Anvisa on Jan. 15, one of the center's
senior officials said on Monday.

The Jan. 15 date brings a measure of clarity to Brazil's
vaccine rollout, which critics have blasted for falling behind
smaller and poorer peers in Latin America. The AstraZeneca
vaccine represents the Brazilian government's main bet to help
end the world's second-most deadly coronavirus outbreak, after
the United States.

"The final submission of this process, this last milestone,
will be on Jan. 15," Marco Krieger, vice president of health
production and innovation at the Rio de Janeiro-based Fiocruz
institute, told Reuters.

Once seen as a front-runner in the development of a
coronavirus vaccine, the British team has been overtaken by U.S.
drugmaker Pfizer Inc and partner BioNTech,
whose shots are already being used in Britain and the United
States.

Confusion has arisen over the best dosage. Data published
earlier from the British team's Phase 3 trials showed efficacy
was 62% for trial participants given two full doses, but a more
robust 90% for a sub-group given first a half, then a full dose.

Krieger said Fiocruz would apply to Anvisa with a two-dose
regimen, which, despite being less effective, was more widely
tested, including in Brazil.

He said Fiocruz would be applying for a full approval with
Anvisa, rather than an emergency use application. Pfizer, which
is in talks to sell its vaccine to Brazil's federal government,
has said the emergency use application is onerous.

Krieger said the institute would start filling and finishing
1 million doses per week in January, then ramp up to 3 million
weekly doses in early February.

Fiocruz is licensed to receive supplies from AstraZeneca and
eventually produce the vaccine locally. Brazil's federal
government, which has ordered the AstraZeneca vaccine, expects
to receive 100 million doses in the first half of 2021.

Brazilian President Jair Bolsonaro, one of the world's most
prominent coronavirus skeptics, said over the weekend he was not
worried about criticism over the speed of Brazil's vaccine
rollout, saying he felt no pressure.

"Nobody pressures me for anything, I don't give a damn about
it," he said in a video aired on CNN Brasil.

Bolsonaro, who caught the virus in July, has also said he
will not take any COVID-19 vaccine, adding to growing vaccine
skepticism in Brazil.

Brazil now has nearly 7.5 million confirmed cases, and
191,139 deaths from the virus since the outbreak began,
according to data from the Health Ministry.
(Reporting by Pedro Fonseca in Rio de Janeiro
Writing by Gabriel Stargardter
Editing by Brad Haynes and Matthew Lewis)

More News
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.